Oral diseases · 2026
Evaluation of the Clinical Efficacy of High-Intensity Focused Ultrasound in the Treatment of Oral Leukoplakia.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yin Jing, Fangchun Chen
Аннотация
OBJECTIVE: This study aimed to evaluate the clinical efficacy of high-intensity focused ultrasound (HIFU) in treating oral leukoplakia (OLK), thereby exploring a novel therapeutic approach for this condition.
METHODS: 17 OLK patients treated at the Department of Oral Mucosal Diseases between June 2022 and February 2023 underwent HIFU therapy. Postoperative clinical efficacy and adverse reactions were evaluated.
RESULTS: At the 6-month follow-up, the outcomes were as follows: complete remission in 9 cases (52.95%), partial remission in 6 cases (35.29%), no remission in 2 cases (11.76%). The overall response rate reached 88.24%. 2 h postoperatively, 2 patients experienced significant pain, while the remaining patients reported mild pain (VAS score: 0.88 ± 1.83, M = 0). Patients with cheeks or commissural leukoplakia showed no swelling. Except for 1 case, patients with dorsal tongue leukoplakia exhibited mild swelling that resolved spontaneously within 2 ~ 24 h. Between 24 and 72 h postoperatively, all 16 patients except one developed noticeable ulcers with mild pain (VAS score: 1.1 ± 0.84, M = 1), which healed within 2-3 weeks.
CONCLUSION: HIFU demonstrates significant clinical efficacy in treating OLK. Postoperative reactions are localized and well-tolerated, markedly improving patients' quality of life.
METHODS: 17 OLK patients treated at the Department of Oral Mucosal Diseases between June 2022 and February 2023 underwent HIFU therapy. Postoperative clinical efficacy and adverse reactions were evaluated.
RESULTS: At the 6-month follow-up, the outcomes were as follows: complete remission in 9 cases (52.95%), partial remission in 6 cases (35.29%), no remission in 2 cases (11.76%). The overall response rate reached 88.24%. 2 h postoperatively, 2 patients experienced significant pain, while the remaining patients reported mild pain (VAS score: 0.88 ± 1.83, M = 0). Patients with cheeks or commissural leukoplakia showed no swelling. Except for 1 case, patients with dorsal tongue leukoplakia exhibited mild swelling that resolved spontaneously within 2 ~ 24 h. Between 24 and 72 h postoperatively, all 16 patients except one developed noticeable ulcers with mild pain (VAS score: 1.1 ± 0.84, M = 1), which healed within 2-3 weeks.
CONCLUSION: HIFU demonstrates significant clinical efficacy in treating OLK. Postoperative reactions are localized and well-tolerated, markedly improving patients' quality of life.